Mahmoud Alimoradi | Machine Learning | Best Researcher Award

Posted on by sciencefather

Mr. Mahmoud Alimoradi | Machine Learning | Best Researcher Award

Lahijan Azad ,Iran

He understands the growing need for Machine Learning and has a keen interest in the field, which he considers a blessing. Recognizing the importance of managing large and complex computations to control various aspects of the human environment has led him into this vast world. He is particularly fascinated by machine learning, especially reinforcement learning, supervised learning, semi-supervised learning, outliers, and basic data challenges. Furthermore, optimization, an area of artificial intelligence that requires fundamental studies and a change in approach, is another of his key research interests.

Profile

Education

He holds a Master’s degree in Artificial Intelligence Engineering from the University of Shafagh, completed in 2020. His thesis was titled “Trees Social Relations Optimization Algorithm: A New Swarm-Based Metaheuristic Technique to Solve Continuous and Discrete Optimization Problems.” He also earned a Bachelor’s degree in Software Engineering from Azad Lahijan University, which he attended from 2007 to 2011.

Research Interests

Theory: Reinforcement Learning (high-dimensional problems, regularized algorithms, model
learning,
representation learning and deep RL, learning from demonstration, inverse optimal control, deep
Reinforcement Learning); Machine Learning (statistical learning theory, nonparametric
algorithms, time series. processes, manifold learning, online learning); Large-scale Optimization;
Evolutionary Computation, Metaheuristic Algorithm, Deep Learning, Healthcare Machine
learning, Big Data, Data Problems (Imbalanced), Signal Analysis
Applications: Automated control, space affairs, robotic control, medicine and health, asymmetric
data, data science, scheduling, proposing systems, self-enhancing systems

Work Experience

He is a freelance programmer with expertise in various operating systems, including Microsoft Windows and Linux (Arch, Ubuntu, Fedora). He is proficient in software tools such as Microsoft Office, Anaconda, Jupyter, PyCharm, Visual Studio, Tableau, RapidMiner, MATLAB, and Visual Studio. His programming skills include Matlab, Python, C++, Scala, Java, and Julia, with a focus on data mining, data science, computer vision, and machine learning. He is experienced with Python libraries like Pandas, Numpy, Matplotlib, Seaborn, PyCV, TensorFlow, Time Series Analysis, Spark, Hadoop, and Cassandra. Additionally, he is skilled in using Github, Docker, and MySQL. His expertise spans machine learning, deep learning, imbalanced data, missing data, semi-supervised learning, healthcare machine learning, algorithm design, and metaheuristic algorithms. He is fluent in English and Persian.

Publications

Nuo Yu | Radiomics | Best Researcher Award

Posted on by sciencefather

Ms. Nuo Yu | Radiomics | Best Researcher Award

Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College ,China

Nuo Yu is a Ph.D. candidate at the Cancer Institute and Hospital of the Chinese Academy of Medical Sciences, specializing in radiation oncology with a focus on esophageal squamous cell carcinoma (ESCC). His research primarily explores innovative chemoradiotherapy regimens to improve treatment outcomes for patients with locally advanced ESCC.

Yu has contributed to several peer-reviewed publications in SCI-indexed journals. Notably, he co-authored a study titled “Conversion Chemoradiotherapy Combined with Nab-Paclitaxel Plus Cisplatin in Patients with Locally Advanced Borderline-Resectable or Unresectable Esophageal Squamous Cell Carcinoma: A Phase I/II Prospective Cohort Study,” published in Strahlentherapie und Onkologie in August 2024. This research evaluated the efficacy and safety of a novel chemoradiotherapy regimen, demonstrating promising results in locoregional control and overall survival rates.

In March 2023, Yu co-authored another significant study, “Efficacy and Safety of Concurrent Chemoradiotherapy Combined with Nimotuzumab in Elderly Patients with Esophageal Squamous Cell Carcinoma: A Prospective Real-world Pragmatic Study,” published in Current Cancer Drug Targets. This research focused on treatment strategies for elderly patients with ESCC, highlighting the potential benefits of combining chemoradiotherapy with nimotuzumab.

Yu’s work has been recognized at international conferences, including presentations at the American Society for Radiation Oncology (ASTRO), the Federation of Asian Organizations for Radiation Oncology (FARO), and the Korean Society for Radiation Oncology (KOSRO). These engagements underscore his active participation in the global radiation oncology community and his commitment to advancing cancer treatment research.

While still in the early stages of his career, Yu’s focused research on ESCC and his contributions to the field of radiation oncology position him as a promising candidate for the Best Researcher Award. Continued efforts to expand his research scope, increase publication impact, and assume leadership roles in larger-scale studies will further strengthen his candidacy.

Profile

Scientific Publications